CRISPR Therapeutics — Third Quarter 2026 Earnings Summary

CRISPR Therapeutics reported third-quarter 2026 revenue of $99 million from CASGEVY, representing a 30% increase quarter-over-quarter and nearly six times the revenue from the same period in 2025. The company expanded CASGEVY approvals to younger children in the U.K., U.A.E., and Bahrain, while the FDA granted Regenerative Medicine Advanced Therapy designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. Clinical progress included the completion of enrollment for the Phase 2 trial of CTX611 in total knee arthroplasty patients and upcoming data presentations for CTX310 and zugo-cel. Financially, the company recorded a net loss of $111.4 million for the quarter, with cash and marketable securities totaling $2.28 billion as of September 30, 2026.